首页> 外文会议>European Association for Clinical Pharmacology and Therapeutics >inhibition of bladder tumor growth by a cyclooxygenase-2 inhibitor and immunosuppression agents in an experimental study
【24h】

inhibition of bladder tumor growth by a cyclooxygenase-2 inhibitor and immunosuppression agents in an experimental study

机译:抑制膀胱肿瘤生长在实验研究中环氧化酶-2抑制剂和免疫抑制剂的抑制作用

获取原文

摘要

We investigated the anti-carcinogenic effects of a cyclooxygenase-2 inhibitor (Celecoxib) and immunosuppression drugs - Sirolimus (SIR) and Cyclosporine (CsA) - on a rat model of bladder cancer induced by N-butyl-N(4-hydroxibutil)nitrosamine (BBN).There was a statistically significant reduction in the incidence of bladder tumors in the SIR (2 mg/kg/day) and CEL (10 mg/kg/day) groups (37.5 and 12.5%, respectively; p<0.05) vs BBN (65%), with less aggressive histological changes, together with significantly lower levels of TGF-|31 and a better redox status (MDA/TAS). SIR 1 mg/kg/day induced a higher nr of tumors. CsA showed no significant effect on bladder carcinogenesis.In conclusion, both Sirolimus (2mg/kg/day) and Celecoxib treatments showed chemopreventive properties for urothelial bladder tumors in rats.
机译:我们研究了环氧化酶-2抑制剂(Celecoxib)和免疫抑制药物 - 西罗莫司(SIR)和环孢菌素(CSA)的抗致癌作用 - 在正丁基-N(4-羟基丙基)亚硝基胺诱导的膀胱癌的大鼠模型上(BBN)。SIR(2mg / kg /天)和CEL(10mg / kg /天)组(37.5%和12.5%分别; P <0.05)的膀胱肿瘤发生率统计学上显着降低与BBN(65%)(65%),具有较少的侵略性组织学变化,以及显着较低的TGF- | 31水平和更好的氧化还原状态(MDA / TAS)。 SIR 1 mg / kg /天诱导肿瘤的较高NR。 CSA对膀胱致癌作用没有显着影响。结论,西罗莫司(2mg / kg /天)和Celecoxib治疗均显示出大鼠尿路上皮膀胱肿瘤的化学预防性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号